Clinical trials: Urinary Bladder Disease
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Blue light cystoscopy (BLC) is a diagnostic procedure in bladder cancer where the inside of the bladder is observed with a camera to detect bladder lesions.
- Trial name
- ENAiBLE (NCT07144319)
- Where
- 12 sites in United States, Belgium and 3 more
- Volunteers
- 500 people
- Sponsor
- Photocure
Non-Muscle Invasive Bladder Cancer
Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer
Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy.
- Trial name
- NCT04859751
- Testing
- VB4-845 Injection
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Bladder Cancer, Prostate Cancer
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.
- Conditions
- Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor
- Trial name
- NCT05696444
- Testing
- RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
- Where
- 6 sites in United States
- Volunteers
- 144 people
- Sponsor
- Medtronic - MITG
Bladder Cancer
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
- Trial name
- RIVERS (NCT07038928)
- Where
- 20 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Overactive Bladder
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.
- Trial name
- NCT01745094
- Testing
- mirabegron, solifenacin
- Where
- 5 sites in Japan
- Volunteers
- 223 people
- Sponsor
- Astellas Pharma Inc
Interstitial Cystitis, Bladder Pain Syndrome
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
This study evaluates the effects of two doses of oral AQX-1125 on bladder pain and other urinary symptoms in subjects with interstitial cystitis/bladder pain syndrome.
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis
- Trial name
- LEADERSHIP 301 (NCT02858453)
- Testing
- AQX-1125 100 mg, AQX-1125 200 mg
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 433 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Bladder Cancer
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
The purpose of this study is to evaluate the efficacy and safety in patients with non-muscle invasive bladder cancer histologically diagnosed to be stage Ta and G1 or G2 and who were randomized into either an EO9 or placebo group…
- Trial name
- NCT01475266
- Testing
- EO9 (Apaziquone)
- Where
- 20 sites in Japan, South Korea
- Volunteers
- 51 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Interstitial Cystitis
Interstitial Cystitis
Patients with interstitial cystitis who meet eligibility requirements will be randomized to one of four treatment arms (3 RTX, Placebo). Study drug is administered as a single instillation within the urinary bladder.
- Trial name
- NCT00056251
- Testing
- H&P; ECG; Blood tests; voiding diary; Cystoscopy
- Where
- 24 sites in United States
- Volunteers
- 150 people
- Sponsor
- ICOS Corporation
Bladder Cancer, Urocystitis
A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder cancer by comparing with clinical standard method…
- Conditions
- Bladder Cancer, Urocystitis, Urinary Bladder Stone, Urothelial Carcinoma
- Trial name
- NCT05337189
- Testing
- Urine DNA methylation analysis, medical imaging and/or cystoscopy and/or pathological examination
- Where
- China
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Overactive Bladder
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
The purpose of this study is to determine the optimal dose of botulinum toxin type A injected in the detrusor muscle to improve urinary symptoms, urodynamic parameters and quality of life of continent women suffering from…
- Trial name
- NCT00578097
- Testing
- Botulinum toxin type A
- Where
- 34 sites in Belgium, Czechia and 6 more
- Volunteers
- 81 people
- Sponsor
- Ipsen
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Overactive Bladder
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910520
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 548 people
- Sponsor
- Allergan
Overactive Bladder, Overactive Bladder (OAB)
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication.
- Conditions
- Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
- Trial name
- DENARA (NCT07209397)
- Testing
- Detrusor nerve radiofrequency ablation
- Where
- 9 sites in United States
- Volunteers
- 202 people
- Sponsor
- InMode MD Ltd.
Urinary Retention
Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
The Spanner is being evaluated for use to manage voiding dysfunction and lower urinary tract symptoms in subjects to achieve bladder drainage in men unfit for other treatments.
- Trial name
- NCT02643849
- Testing
- The Spanner Temporary Prostatic Stent
- Where
- 6 sites in United States
- Volunteers
- 107 people
- Sponsor
- SRS Medical
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients
This is a safety and efficacy study of BOTOX® (Botulinum Toxin Type A) in the Treatment of Adult Korean Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity or Overactive Bladder.
- Trial name
- NCT02601287
- Testing
- Botulinum Toxin Type A
- Where
- 5 sites in South Korea
- Volunteers
- 168 people
- Sponsor
- Allergan
Stress Urinary Incontinence
Vesair Balloon Confirmatory Trial (VECTOR)
Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months.
- Trial name
- VECTOR (NCT03794206)
- Testing
- Vesair Balloon
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Solace Therapeutics, Inc.
Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-DWJ155 and the safety and imaging properties of [68Ga]Ga-DWJ155 in patients with…
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
- Trial name
- NCT07660055
- Testing
- [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Overactive Bladder
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world…
- Trial name
- NCT05067478
- Testing
- Vibegron
- Where
- 64 sites in United States
- Volunteers
- 403 people
- Sponsor
- Urovant Sciences GmbH
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
- Trial name
- FORAGER-2 (NCT07218380)
- Testing
- Vepugratinib, EV, Pembrolizumab
- Where
- 276 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc